Program Transfer. Licensee may transfer the Program and all of Licensee’s license rights and obligations to another party only if that party agrees to the terms of this Agreement. If the license is terminated for any reason by either party, Licensee is prohibited from transferring the Program to another party. Licensee may not transfer a portion of 1) the Program or 2) the Program’s Authorized Use. When Licensee transfers the Program, Licensee must also transfer a hard copy of this Agreement, including the LI and XxX. Immediately after the transfer, Licensee’s license terminates.
Program Transfer. A. In the event that a program to which unit members are assigned is eliminated or suspended at one site and transferred to another site which requires the relocation by a participating unit member of more than fifty (50) miles, such unit members who relocate with the program shall be reimbursed for actual, reasonable and necessary household moving expenses.
B. The University shall provide advance notice at the time such program transfers are anticipated for the purpose of discussing the proposed action.
C. If less than one hundred twenty (120) days notice of a program transfer is provided, the University shall reimburse a participating unit member for actual, reasonable and necessary temporary housing expenses for a number of days not exceeding the difference between one hundred twenty days and the actual notice in days.
Program Transfer. The Department may transfer entire programs. The Department will notify the affected employee(s) in writing five (5) working days in advance of the transfer. The Department will notify the affected employee(s) in writing thirty (30) days in advance of transfers involving a change in the employee’s official workstation of twenty-five (25) miles or more.
Program Transfer. Transferring from one Medical Center sponsored GME Program to another Medical Center sponsored GME Program during an appointment period covered by this AGREEMENT is prohibited unless:
(A) Resident requests in writing to his/her Program Director to be released, and;
(B) The request for release is approved in writing by his/her Program Director, and;
(C) The request for release is approved by the GMEC. The GMEC, in its sole and absolute discretion, shall determine if there is to be a release from this AGREEMENT. If a release is approved, it is understood that such release shall not take place unless and until there is satisfactory completion of all current obligations and responsibilities of the current GME Program by Resident and such completion is affirmed in writing by the Program Director.
Program Transfer. If Merck elects to terminate the Research Program as provided in Section 14.1 upon [*], then Merck shall have [*]. If, in addition, in such case Merck desires to [*]. Promptly following Merck’s provision of such notice, [*]. Any such Research Program Development Candidate that [*]. In furtherance of the foregoing, NGM [*]. For clarity, [*].
Program Transfer. If ATL exercises its right under clause 19.1(h), Cortendo shall:
(a) and (with effect from the date that ATL exercises such right) it hereby does, grant to ATL, an exclusive, worldwide, royalty-bearing, perpetual, transferable licence, with the right to sub-license, under the Cortendo IP and Joint IP to exploit the technology that is the subject of the Cortendo IP and Joint IP for any purpose or indication and in any;
(b) transfer to ATL as soon as reasonably practicable all Development Data, and any reports, records, materials and information resulting from Cortendo’s performance under this agreement and/or in Cortendo’s or its Affiliates’ control relating to ATL1103 or ATL1103 Products as may be necessary to enable ATL to practice such licence;
(c) transfer and assign to ATL all of its right, title and interest in and to all INDs, registration applications, drug dossiers and master files with respect to any and all ATL1103 Products and all Marketing Approvals with respect to any and all ATL1103 Products;
(d) to the extent Cortendo is permitted to do so under each sublicense agreement, continue each such sublicense agreement entered into by Cortendo with a Sub-Licensee in full force and effect in accordance with the terms and conditions of the respective sublicense agreements, and assign each such sublicense agreement to ATL;
(e) to the extent Cortendo is permitted to do so under the relevant agreement, continue each agreement with Third Party subcontractors who are performing studies or activities relating to this agreement in full force and effect in accordance with the terms and conditions of the respective Third Party agreements, provided that ATL shall be responsible for all obligations of Cortendo under any such agreement that arise on and after the effective date of such termination, and assign each such Third Party Agreement to ATL (having paid all amounts due under such agreement up until the effective date of assignment); and
(f) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights provided for under this clause 19.2 to ATL (collectively, the Program Transfer).
Program Transfer. 13.7.1 Upon the termination of this Agreement in whole or with respect to either the Oncology Field or the Non-Oncology Field, in addition to any other remedies available at law or in equity, and in addition to its obligations pursuant to Section 13.6, Licensee:
(a) shall promptly transfer to Symphony (or its designee) or provide copies of all tangible documentation, know-how, data, reports, records or other materials or information, whether written or electronic, that is Controlled by Licensee embodying or related to the Licensed IP, Regulatory Files, XL647 or, as applicable, the Oncology Program or the Non-Oncology Program;
(b) shall promptly provide Symphony (or its designee) with all information regarding, and execute all documents, reasonably necessary or desirable to transfer to Symphony (or its designee) all, Regulatory Files in Licensee’s name;
(c) agrees to negotiate in good faith to grant Symphony, on commercially reasonably terms, a worldwide license under the Licensee XL647 IP (with the right to grant sublicenses through one or more tiers of sublicensees) to develop, make, have made, use, offer for sale, sell and import Licensed Products in the Field;
(d) to the extent Licensee owns or holds any right, title and interest in any trademarks under which any Licensed Product has been or is being marketed or sold in the Field, assigns the same to Symphony; and
(e) shall promptly transfer or use commercially reasonable efforts to assist Symphony (or its designee) to obtain all other materials, documentation, processes, Third Party licenses, and other items used by Licensee or any Third Party in connection with the performance of this Agreement to the extent necessary for Symphony (or its designee) to continue the development and commercialization of Licensed Products in the Field; provided, however, that if this Agreement is terminated with respect to only either the Oncology Field or the Non-Oncology Field, the foregoing obligations shall be limited to the terminated field.
Program Transfer. You may permanently transfer all of your rights under this License, provided the recipient agrees to the terms of this License and you agree to remove all elements of the Program from your from your home or portable computer.
Program Transfer. (a) If this Agreement expires pursuant to Section 19.1(a) or 19.1(b) in its entirety or for a particular Indication, or if this Agreement is terminated in its entirety or in a particular country, Indication or Licensed Product by Sanofi pursuant to Section 19.4(b), or by Selecta pursuant to Sections 19.3, 19.6 or 19.7, then, Selecta shall have thirty (30) days, to notify Sanofi in writing that it wishes to continue developing a Research Vaccine Candidate, Development Candidate or Licensed Product within the scope of such expiration or termination (such written request, a “Transfer Notice”). After receiving a Transfer Notice, Sanofi shall promptly:
(i) transfer or provide copies of (and if available provide electronic copies of), at [***]’s sole expense, to Selecta (or its designee) all Know-How, Inventions, data, reports, clinical and other business records, correspondence and materials (including all CMC Data and pre-clinical and clinical data) in Sanofi’s or its Affiliates’ or Sublicensees’ possession or control that relate to the Research Vaccine Candidates, Development Candidate or Licensed Product, either in the Territory or with respect to the terminated country, Indication or Licensed Product;
(1) provide (and if available provide electronic copies of), at [***]’s sole expense, to Selecta (or its designee) all information within or relating to, and (2) assign, and hereby assigns, and execute all documents, reasonably necessary [***] to assign and [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. transfer to Selecta (or its designee) all right, title and interest in and to, in each case ((1) and (2)) all Regulatory Filings and Regulatory Approvals (including drafts thereof) with respect to the Research Vaccine Candidates, Development Candidate or Licensed Product, either in the Territory or with respect to the terminated country, Indication or Licensed Product;
(iii) grant, and hereby grants, to Selecta a royalty bearing, exclusive (even as to Sanofi) license (with the right to grant sublicenses through multiple tiers) under all Patents, Know-How and Inventions owned by Sanofi or any of its Affiliates (including Joint Collaboration Technology and Sanofi Collaboration Technology), on or after the Effective Date, in the Territory (other than the commercialization license, which will be limited to th...
Program Transfer. LICENSEE may transfer the Program and all of LICENSEE's license rights and obligations to another party only if that party agrees to the terms of this Agreement and with the consent of BPD in writing. If the license is terminated for any reason by either party, LICENSEE is prohibited from transferring the Program to another party. LICENSEE may not transfer a portion of 1) the Program or 2) the Program's Authorised Use. When LICENSEE transfers the Program, LICENSEE must also transfer a hard copy of this Agreement, including ECert. Immediately after the transfer, LICENSEE's license terminates.
